Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
melphalan + dexamethasone
- Development stage
- Unknown
- Lead developer
- 3T Ophthalmics
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
melphalan + dexamethasone is a combination therapeutic being developed by 3T Ophthalmics for the treatment of intraocular cancers, specifically retinoblastoma and uveal melanoma. The combination consists of melphalan, a potent DNA-alkylating cytotoxic agent, and dexamethasone, a glucocorticoid receptor agonist that provides anti-inflammatory effects. The treatment is delivered using 3T Ophthalmics' proprietary Targeted Episcleral Delivery System (TEDS), a periocular reservoir device placed under the conjunctiva in contact with the episclera. This delivery method enables sustained and controlled release of the chemotherapeutic agents directly to the posterior segment of the eye, achieving high local concentrations while minimizing systemic exposure and associated side effects.
- Other names
- Episcleral Melphalan + DexamethasoneTEDS Melphalan + Dexamethasone
02
Targets
DNAGR (Glucocorticoid receptor)
Beyond the preview
Go deeper on melphalan + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on melphalan + dexamethasone.